Eckert & Ziegler BEBIG Half-Year 2011 Results
(Thomson Reuters ONE) -
Regulated information
Eckert & Ziegler BEBIG Half-Year 2011 Results
Seneffe, Belgium, August 2, 2011, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB), a global leader in brachytherapy,
announced today its consolidated results for the first half-year ending June
30, 2011.
The Half-Year 2011 report including the management report and condensed
consolidated interim financial statements for the 6 months ending June 30, 2011
can be downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html
It should be mentioned that comparability to the year 2010 is limited as the
Russian project contributed significantly to the revenue and earnings in 2010,
while no revenue was generated out of the project in 2011.
Sales for the first six months of 2011 reached EUR 13.1 million, compared to EUR
14.9 million for the same period of 2010, showing a decrease of 12%. The main
components were income generated by the sales of permanent brachytherapy I-125
radiotherapeutic implants as well as income from temporary brachytherapy
equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192)
sources (also called "afterloaders"). The difference in sales was expected by
management, it relates to the limited comparability of this first semester 2011
versus 2010.
Earnings before interests and taxes (EBIT) reached EUR 1.5 million for the first
semester of 2011 compared to EUR 2.6 million for the same period of 2010,
showing a decrease of the EBIT margin by 6%, from 18% to 12%. The magnitude of
this decrease was expected by the management, due to the fact that construction
projects, like Russia in the past two years, contribute with very strong
margins, while no revenue out of construction contracts were recorded this year
so far. These kinds of projects are recurring, but will not contribute on a
constant basis.
Net profit reached EUR 0.7 million end of June 2011 compared to a net profit of
EUR 1.7 million end of June 2010.
Total equity of the group stood at EUR 38.3 million on June 30, 2011 versus EUR
37.6 million in December 31, 2010.
Outlook
As it was anticipated, the management does not expect to reach the sales level
of 2010; mainly because revenues generated by the Russian project contributed
significantly to the total turnover in 2010, while no revenues from that project
are recognized in 2011.
For the full year 2011, taking into account our current order book and seasonal
fluctuations, management expects to have revenues from sales of goods to be
above the 2010 results even if revenues and profitability for this first half-
year 2011 were slightly behind management expectation. The price pressure in the
European public health care sector is continuing to affect our niche market for
permanent brachytherapy. Although business in developing countries is robust
with reliable profitability, the risk for our market in Russia is increasing.
The current crisis of the EURO adds risks to our receivables, especially in
European countries affected by high public debts. Under these boundary
conditions the management expects an EBIT margin for the year end in the
magnitude of 13%.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the Euronext stock exchange since April 1997.
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email:ir(at)bebig.eu
Website:www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1535344]
Unternehmensinformation / Kurzprofil:
Datum: 02.08.2011 - 07:42 Uhr
Sprache: Deutsch
News-ID 56892
Anzahl Zeichen: 5332
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG Half-Year 2011 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
